Does Rallies show 13F holders for CTMX?

Yes. Rallies tracks hedge fund and 13F ownership data for CTMX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CTMX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CTMX. It does not provide personalized investment advice.

CTMX (CytomX Therapeutics, Inc.) Stock Analysis - Hedge Fund Holdings

CytomX Therapeutics, Inc. (CTMX) is a publicly traded Healthcare sector company. As of May 21, 2026, CTMX trades at $3.74 with a market cap of $761.96M and a P/E ratio of 0.00. CTMX moved +2.06% today. Year to date, CTMX is -9.71%; over the trailing twelve months it is +80.58%. Its 52-week range spans $0.40 to $8.21. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces CTMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CTMX stock?

Hedge funds tracked by Rallies that own CTMX include Orbimed Advisors and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CytomX Therapeutics, Inc..

CTMX Key Metrics

Key financial metrics for CTMX
Metric	Value
Price	$3.74
Market Cap	$761.96M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$8.21
52-Week Low	$0.40
Volume	21
Avg Volume	0
Revenue (TTM)	$35.54M
Net Income	$-59.14M
Gross Margin	0.00%

Top Hedge Funds Holding CTMX

Orbimed Advisors holds 3.53M shares of CTMX, changed -58.33% as of Dec 31, 2025.
Mangrove Partners holds 26.27K shares of CTMX, changed +0.00% as of Mar 31, 2026.

Latest CTMX News

CytomX Raises $250M, Holds $346.7M Cash; Varseta-M Dose Expansion Completes Enrollment — May 7, 2026
CytomX Therapeutics Prices $250M Offering of 45.99M Shares at $5.30 — Mar 18, 2026
CytomX Initiates $250M Offering as Varseta-M Phase I Shows 32% Response — Mar 17, 2026
CytomX Launches $250M Stock Offering with $37.5M Overallotment Option — Mar 16, 2026
CytomX Targets Multibillion-Dollar Market with Varseta-M Registrational Trial — Mar 16, 2026

Recent CTMX Insider Trades

Chu Yu-Waye sold 21.28K (~$136.68K) on Mar 17, 2026.
McCarthy Sean A. sold 118.97K (~$764.14K) on Mar 17, 2026.
BELVIN MARCIA sold 31.49K (~$202.27K) on Mar 17, 2026.

CTMX Analyst Consensus

9 analysts cover CTMX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.

Common questions about CTMX

Who owns CTMX stock?: Hedge funds tracked by Rallies that own CTMX include Orbimed Advisors and Mangrove Partners. The latest tracked quarter is Dec 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for CytomX Therapeutics, Inc..
Does Rallies show 13F holders for CTMX?: Yes. Rallies tracks hedge fund and 13F ownership data for CTMX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CTMX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CTMX. It does not provide personalized investment advice.